Please enable JavaScript to continue using this application.

Compare $SRZN vs $ZNTL | Chartloom

Compare

$SRZN vs $ZNTL

Surrozen Inc · Zentalis Pharmaceuticals Inc

SRZN

Surrozen Inc

ZNTL

Zentalis Pharmaceuticals Inc

Compare $SRZN vs $ZNTL

Comparing Surrozen Inc and Zentalis Pharmaceuticals Inc

SRZNSurrozen Inc

ZNTLZentalis Pharmaceuticals Inc

SRZNSurrozen Inc

Market cap

$345M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

118.58x

Rev growth (TTM)

-8.8%

YTD performance

37.8%

52W performance

111.5%

FCF yield

-10.1%

ZNTLZentalis Pharmaceuticals Inc

Market cap

$188M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

92.7%

52W performance

61.0%

FCF yield

-68.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SRZN

ZNTL

Detailed metrics comparison

SRZN

Surrozen Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

SRZN$345M

ZNTL$188M

Enterprise Value

SRZN$243M

ZNTL$163M

Price

SRZN$29.69

ZNTL$2.64

P/E Ratio

SRZNN/A

ZNTLN/A

P/S Ratio

SRZN29.95x

ZNTL0.00x

EV/Sales

SRZN21.08x

ZNTL0.00x

EV/EBITDA

SRZN0.00x

ZNTL0.00x

P/B Ratio

SRZN7.31x

ZNTL1.70x

P/FCF Ratio

SRZNN/A

ZNTLN/A

EV/FCF

SRZN-6.94x

ZNTL-1.27x

PEG Ratio

SRZNN/A

ZNTLN/A

Forward P/E (NTM)

SRZNN/A

ZNTLN/A

Forward P/S (NTM)

SRZN118.58x

ZNTLN/A

Revenue (TTM)

SRZN$12M

ZNTL$0

Revenue Growth (YoY)

SRZN-8.8%

ZNTLN/A

Forward Rev Growth

SRZN-82.6%

ZNTL447.5%

Gross Margin (TTM)

SRZN0.0%

ZNTL0.0%

Operating Margin (TTM)

SRZN0.0%

ZNTL0.0%

EBITDA Margin (TTM)

SRZN-383.4%

ZNTL0.0%

Net Margin (TTM)

SRZN-2885.3%

ZNTL0.0%

FCF Margin (TTM)

SRZN-303.9%

ZNTLN/A

Net Income (TTM)

SRZN$-332M

ZNTL$-62M

FCF (TTM)

SRZN$-35M

ZNTL$-128M

EPS (TTM)

SRZN-$28.48

ZNTL$0.00

ROE (TTM)

SRZN58.2%

ZNTL-5277.0%

ROA (TTM)

SRZN-30962.0%

ZNTL-4055.0%

ROIC (TTM)

SRZN58.2%

ZNTL-5277.0%

Cash

SRZN$102M

ZNTL$25M

Debt

SRZN$0

ZNTL$0

Net Cash/Debt

SRZN$102M

ZNTL$25M

Current Ratio (TTM)

SRZN12.14x

ZNTL4.82x

Quick Ratio (TTM)

SRZN11.88x

ZNTL4.64x

Debt/Equity (TTM)

SRZN0.00x

ZNTL0.00x

Debt/Assets (TTM)

SRZN0.0%

ZNTL0.0%

Interest Coverage (TTM)

SRZNN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

SRZN0.00x

ZNTL0.00x

Beta

SRZN0.53

ZNTL1.92

52W Performance

SRZN111.5%

ZNTL61.0%

YTD Performance

SRZN37.8%

ZNTL92.7%

% from 52W High

SRZN-21.5%

ZNTL-62.0%

% from 52W Low

SRZN160.7%

ZNTL117.8%

Asset Turnover (TTM)

SRZN0.11x

ZNTL0.00x

FCF Yield (TTM)

SRZN-10.1%

ZNTL-68.2%

Earnings Yield (TTM)

SRZN-96.4%

ZNTL-32.9%

Dividend Yield (TTM)

SRZNN/A

ZNTLN/A

Rule of 40

SRZN-312.7

ZNTL0.0

EV/GP/RG

SRZNN/A

ZNTLN/A

Ticker research

View SRZN research View ZNTL research

Metric	SRZN Surrozen Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$345M	$188M
Enterprise Value	$243M	$163M
Price	$29.69	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	29.95x	0.00x
EV/Sales	21.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	1.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.94x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	118.58x	N/A
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	-8.8%	N/A
Forward Rev Growth	-82.6%	447.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-383.4%	0.0%
Net Margin (TTM)	-2885.3%	0.0%
FCF Margin (TTM)	-303.9%	N/A
Net Income (TTM)	$-332M	$-62M
FCF (TTM)	$-35M	$-128M
EPS (TTM)	-$28.48	$0.00
ROE (TTM)	58.2%	-5277.0%
ROA (TTM)	-30962.0%	-4055.0%
ROIC (TTM)	58.2%	-5277.0%
Financial Health
Cash	$102M	$25M
Debt	$0	$0
Net Cash/Debt	$102M	$25M
Current Ratio (TTM)	12.14x	4.82x
Quick Ratio (TTM)	11.88x	4.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.53	1.92
52W Performance	111.5%	61.0%
YTD Performance	37.8%	92.7%
% from 52W High	-21.5%	-62.0%
% from 52W Low	160.7%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-10.1%	-68.2%
Earnings Yield (TTM)	-96.4%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-312.7	0.0
EV/GP/RG	N/A	N/A
Ticker research	View SRZN research	View ZNTL research

Valuation

P/S Ratio

ZNTL

0.00x

SRZN

29.95x

EV/FCF

SRZN

-6.94x

ZNTL

-1.27x

Growth & revenue

Revenue Growth TTM

SRZN

-8.8%

Forward Revenue Growth

ZNTL

447.5%

SRZN

-82.6%

Profitability & performance

Gross Margin

SRZN

0.0%

ZNTL

0.0%

ROE

SRZN

58.2%

ZNTL

-5277.0%

FCF Yield %

SRZN

-10.1%

ZNTL

-68.2%

52-Week Performance

SRZN

111.5%

ZNTL

61.0%

Detailed metrics comparison

SRZN

Surrozen Inc

ZNTL

Zentalis Pharmaceuticals Inc

Market Cap

SRZN$345M

ZNTL$188M

Enterprise Value

SRZN$243M

ZNTL$163M

Price

SRZN$29.69

ZNTL$2.64

P/E Ratio

SRZNN/A

ZNTLN/A

P/S Ratio

SRZN29.95x

ZNTL0.00x

EV/Sales

SRZN21.08x

ZNTL0.00x

EV/EBITDA

SRZN0.00x

ZNTL0.00x

P/B Ratio

SRZN7.31x

ZNTL1.70x

P/FCF Ratio

SRZNN/A

ZNTLN/A

EV/FCF

SRZN-6.94x

ZNTL-1.27x

PEG Ratio

SRZNN/A

ZNTLN/A

Forward P/E (NTM)

SRZNN/A

ZNTLN/A

Forward P/S (NTM)

SRZN118.58x

ZNTLN/A

Revenue (TTM)

SRZN$12M

ZNTL$0

Revenue Growth (YoY)

SRZN-8.8%

ZNTLN/A

Forward Rev Growth

SRZN-82.6%

ZNTL447.5%

Gross Margin (TTM)

SRZN0.0%

ZNTL0.0%

Operating Margin (TTM)

SRZN0.0%

ZNTL0.0%

EBITDA Margin (TTM)

SRZN-383.4%

ZNTL0.0%

Net Margin (TTM)

SRZN-2885.3%

ZNTL0.0%

FCF Margin (TTM)

SRZN-303.9%

ZNTLN/A

Net Income (TTM)

SRZN$-332M

ZNTL$-62M

FCF (TTM)

SRZN$-35M

ZNTL$-128M

EPS (TTM)

SRZN-$28.48

ZNTL$0.00

ROE (TTM)

SRZN58.2%

ZNTL-5277.0%

ROA (TTM)

SRZN-30962.0%

ZNTL-4055.0%

ROIC (TTM)

SRZN58.2%

ZNTL-5277.0%

Cash

SRZN$102M

ZNTL$25M

Debt

SRZN$0

ZNTL$0

Net Cash/Debt

SRZN$102M

ZNTL$25M

Current Ratio (TTM)

SRZN12.14x

ZNTL4.82x

Quick Ratio (TTM)

SRZN11.88x

ZNTL4.64x

Debt/Equity (TTM)

SRZN0.00x

ZNTL0.00x

Debt/Assets (TTM)

SRZN0.0%

ZNTL0.0%

Interest Coverage (TTM)

SRZNN/A

ZNTLN/A

Net Debt/EBITDA (TTM)

SRZN0.00x

ZNTL0.00x

Beta

SRZN0.53

ZNTL1.92

52W Performance

SRZN111.5%

ZNTL61.0%

YTD Performance

SRZN37.8%

ZNTL92.7%

% from 52W High

SRZN-21.5%

ZNTL-62.0%

% from 52W Low

SRZN160.7%

ZNTL117.8%

Asset Turnover (TTM)

SRZN0.11x

ZNTL0.00x

FCF Yield (TTM)

SRZN-10.1%

ZNTL-68.2%

Earnings Yield (TTM)

SRZN-96.4%

ZNTL-32.9%

Dividend Yield (TTM)

SRZNN/A

ZNTLN/A

Rule of 40

SRZN-312.7

ZNTL0.0

EV/GP/RG

SRZNN/A

ZNTLN/A

Ticker research

View SRZN research View ZNTL research

Metric	SRZN Surrozen Inc	ZNTL Zentalis Pharmaceuticals Inc
Market & Valuation
Market Cap	$345M	$188M
Enterprise Value	$243M	$163M
Price	$29.69	$2.64
P/E Ratio	N/A	N/A
P/S Ratio	29.95x	0.00x
EV/Sales	21.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	1.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.94x	-1.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	118.58x	N/A
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	-8.8%	N/A
Forward Rev Growth	-82.6%	447.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-383.4%	0.0%
Net Margin (TTM)	-2885.3%	0.0%
FCF Margin (TTM)	-303.9%	N/A
Net Income (TTM)	$-332M	$-62M
FCF (TTM)	$-35M	$-128M
EPS (TTM)	-$28.48	$0.00
ROE (TTM)	58.2%	-5277.0%
ROA (TTM)	-30962.0%	-4055.0%
ROIC (TTM)	58.2%	-5277.0%
Financial Health
Cash	$102M	$25M
Debt	$0	$0
Net Cash/Debt	$102M	$25M
Current Ratio (TTM)	12.14x	4.82x
Quick Ratio (TTM)	11.88x	4.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.53	1.92
52W Performance	111.5%	61.0%
YTD Performance	37.8%	92.7%
% from 52W High	-21.5%	-62.0%
% from 52W Low	160.7%	117.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-10.1%	-68.2%
Earnings Yield (TTM)	-96.4%	-32.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-312.7	0.0
EV/GP/RG	N/A	N/A
Ticker research	View SRZN research	View ZNTL research